106 related articles for article (PubMed ID: 19154240)
1. The risks and benefits of switching antipsychotics: a case study approach.
Weber M; Gutierrez AM; Mohammadi M
Perspect Psychiatr Care; 2009 Jan; 45(1):54-61. PubMed ID: 19154240
[TBL] [Abstract][Full Text] [Related]
2. The risks and benefits of switching patients with schizophrenia or schizoaffective disorder from two to one antipsychotic medication: a randomized controlled trial.
Constantine RJ; Andel R; McPherson M; Tandon R
Schizophr Res; 2015 Aug; 166(1-3):194-200. PubMed ID: 26141142
[TBL] [Abstract][Full Text] [Related]
3. Putting metabolic side effects into perspective: risks versus benefits of atypical antipsychotics.
Meltzer HY
J Clin Psychiatry; 2001; 62 Suppl 27():35-9; discussion 40-1. PubMed ID: 11806488
[TBL] [Abstract][Full Text] [Related]
4. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
[TBL] [Abstract][Full Text] [Related]
5. [Type 2 diabetes and dyslipidemia. Side effects of "Atypical" neuroleptics?].
Wetterling T
Med Klin (Munich); 2003 Jul; 98(7):364-7. PubMed ID: 12937901
[TBL] [Abstract][Full Text] [Related]
6. Reducing the burden of side effects during long-term antipsychotic therapy: the role of "switching" medications.
Weiden PJ; Buckley PF
J Clin Psychiatry; 2007; 68 Suppl 6():14-23. PubMed ID: 17650055
[TBL] [Abstract][Full Text] [Related]
7. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.
Kane JM; Leucht S; Carpenter D; Docherty JP;
J Clin Psychiatry; 2003; 64 Suppl 12():5-19. PubMed ID: 14640142
[TBL] [Abstract][Full Text] [Related]
8. Assessing cardiovascular risks versus clinical benefits of atypical antipsychotic drug treatment.
Meltzer HY; Davidson M; Glassman AH; Vieweg WV
J Clin Psychiatry; 2002; 63 Suppl 9():25-9. PubMed ID: 12088173
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study.
Wang X; Savage R; Borisov A; Rosenberg J; Woolwine B; Tucker M; May R; Feldman J; Nemeroff CB; Miller AH
J Psychiatr Res; 2006 Oct; 40(7):669-76. PubMed ID: 16762371
[TBL] [Abstract][Full Text] [Related]
10. Switching antipsychotic medications: a 2-year chart-review study exploring patient characteristics and psychiatric service use of schizophrenia patients.
Schneider AL; Mosier KE; Tempier RP
J Clin Psychiatry; 2009 Jun; 70(6):937-9. PubMed ID: 19573492
[No Abstract] [Full Text] [Related]
11. Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study.
Alptekin K; Hafez J; Brook S; Akkaya C; Tzebelikos E; Ucok A; El Tallawy H; Danaci AE; Lowe W; Karayal ON
Int Clin Psychopharmacol; 2009 Sep; 24(5):229-38. PubMed ID: 19531959
[TBL] [Abstract][Full Text] [Related]
12. Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims.
Lambert BL; Chou CH; Chang KY; Tafesse E; Carson W
Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):417-25. PubMed ID: 15786516
[TBL] [Abstract][Full Text] [Related]
13. Do certain atypical antipsychotics increase the risk of diabetes? A critical review of 17 pharmacoepidemiologic studies.
Ramaswamy K; Masand PS; Nasrallah HA
Ann Clin Psychiatry; 2006; 18(3):183-94. PubMed ID: 16923657
[TBL] [Abstract][Full Text] [Related]
14. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study.
Byerly MJ; Marcus RN; Tran QV; Eudicone JM; Whitehead R; Baker RA
Schizophr Res; 2009 Feb; 107(2-3):218-22. PubMed ID: 19038534
[TBL] [Abstract][Full Text] [Related]
15. Using antipsychotic agents in older patients.
Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
[TBL] [Abstract][Full Text] [Related]
16. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
Henderson DC; Cagliero E; Gray C; Nasrallah RA; Hayden DL; Schoenfeld DA; Goff DC
Am J Psychiatry; 2000 Jun; 157(6):975-81. PubMed ID: 10831479
[TBL] [Abstract][Full Text] [Related]
17. Evidence of switching antipsychotic therapy to improve metabolic disturbances.
Wieden PJ; Newcomer JW
J Clin Psychiatry; 2007 May; 68(5):e13. PubMed ID: 17503971
[No Abstract] [Full Text] [Related]
18. Strategies for dosing and switching antipsychotics for optimal clinical management.
Buckley PF; Correll CU
J Clin Psychiatry; 2008; 69 Suppl 1():4-17. PubMed ID: 18484804
[TBL] [Abstract][Full Text] [Related]
19. Fast Versus Slow Strategy of Switching Patients With Schizophrenia to Aripiprazole From Other Antipsychotics.
Hwang TJ; Lo WM; Chan HY; Lin CF; Hsieh MH; Liu CC; Liu CM; Hwu HG; Kuo CH; Chen WJ
J Clin Psychopharmacol; 2015 Dec; 35(6):635-44. PubMed ID: 26488675
[TBL] [Abstract][Full Text] [Related]
20. Weight gain and lipid-glucose profiles among patients taking antipsychotic medications: comparisons for prescriptions administered using algorithms versus usual care.
Koch DA; Scott AJ
J Psychiatr Ment Health Nurs; 2012 Jun; 19(5):389-94. PubMed ID: 22070226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
